「Biophysics and Physicobiology」に Atsushi Hijikata, Clara Shionyu, Setsu Nakae, Masafumi Shionyu, Motonori Ota, Shigehiko Kanaya, Tsuyoshi Shirai による "Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins" を掲載

2021年10月20日 学会誌

日本生物物理学会欧文誌［Biophysics and Physicobiology］に以下の論文が公開されました。

Atsushi Hijikata, Clara Shionyu, Setsu Nakae, Masafumi Shionyu, Motonori Ota, Shigehiko Kanaya, Tsuyoshi Shirai
"Current status of structure-based drug repurposing against COVID-19 by targeting SARS-CoV-2 proteins"

【Significance】
There is still a strong requirement of effective therapeutics for overcoming the COVID-19 pandemic. Up to 68% of the total amino acid residues encoded in the SARS-CoV-2 genome have been currently covered by the structural data. The recent activities in drug discovery against COVID-19 are reviewed in this article with emphasizing a protein structure-based approaches.

Biophysics Physicobiology, 2021, Volume 18, Pages 226-240


URL: https://doi.org/10.2142/biophysico.bppb-v18.025

シェア